ASX Lookahead

ASX Lookahead

Equities 6 minutes to read

Summary:  We look at potential drivers of Aussie stocks into year end and ahead to 2021. Can the ASX 200 lose the laggard status.


As we detailed in November, the vaccine trials have been higher than people expected in terms of efficacy. Giving equity markets broadly the luxury of glossing over near-term risks and focussing on the prospects of vaccine rollout and activity normalising next year. Hence, we continue to remain constructive on a medium-term outlook and focus on using any corrections to add to reopening trades (E.g. Cyclicals, small caps, commodities, emerging markets). For pro-cyclical stocks there is more room for normalisation and these sectors can look past immediate risks through to benefits a vaccine can provide.

Australia, despite having outperformed with respect to the COVID induced economic hit has lagged DM peers in terms of equity market performance. Australia’s relative success in containing the virus lends less relative upside from the vaccine. In addition, Asia also benefitting from the engine of China’s reflationary regime with broad scale infrastructure and construction stimulus, along with continued dollar weakness supporting flows into higher beta emerging markets. Added for Asia is a more favourable geopolitical tailwind with the incoming Biden administration expected to be less volatile in their approach to China vs. Australia still very much in the thick of an ongoing spat with China.

Although there are individual stocks and sectors that have been impacted by the AU/China tensions, the reopening and recovery in earnings and economic growth should take precedent at an index level. (Caveat – providing high value exports like iron ore do not come into the mix). In addition, for Australia the aggressive virus elimination strategy, with international border restrictions seemingly in place for a lengthy period at this stage, is an ongoing headwind for education and tourism – two high value services exports. 

However, the period ahead should bring plenty of opportunity for catch up, particularly taking into consideration the ongoing and overwhelming virus caseload, lockdowns and economic drags experienced by other regions, compared to a relatively virus free Australia. Of course, the hit to global activity and restrictive measures in place domestically still present a drag on Australia’s economy, but with a vaccine rollout ahead, earnings rebound in play and the prospect of regional travel bubbles in the pipeline Investors have something to look forward to which should see the index on a better footing into year end.

In addition, the resource heavy nature of the index could see the index shifting from underperformer to outperformer in the year ahead as various commodities rev-up into 2021 with a vaccine rollout, demand bounce back and fiscal spending tailwinds. Exposure to other investing thematics like the ESG/green transformation via battery metals, rare earths, copper and the like, also providing opportunity for investors.

As we transition toward an inflationary regime, with a synchronised global growth reacceleration coupled with unprecedented liquidity injections against the backdrop of extraordinary fiscal stimulus, we see a shift in market leadership toward cyclical sectors and geographies, real economy stocks, non-US markets and commodities. Therefore, the more cyclically orientated nature of the ASX 200 should support index performance throughout 2021 as the reflation rotation takes charge.

Financials, a heavyweight on the index will also be a driver in the year ahead. The rebounding growth picture along with higher yields supports the asset allocation from a macro standpoint. In addition for Australian banks a recovery in the housing market, buybacks, and better than expected outcome for bad debts will support the outlook for the sector.

For commodities, huge supply deficits with structural underinvestment, a vaccine-led recovery in global demand, green transformation tailwinds, and the engines of a weaker dollar plus higher inflation, coincide with a historic underweighting and a multiyear bear market to bring a broad commodity rally in 2021 – A trend that Australian stocks will benefit from.

Australian stocks with an abundance of commodity exposures present many selective buying opportunities for investors, as this regime shift is undertaken.

Energy - Aus Energy Sector still trades well below pre-COVID levels

Santos (STO:xasx)

Beach Energy (BPT:xasx)

Oil Search (OSH:xasx)

Copper – Green electrification tailwinds meets supply deficits

OZ Minerals (OZL:xasx)

Sandfire (SFR:xasx)

Lithium/Nickel – Green energy/EVs/Battery Metal

Orecobre (ORE:xasx)

Galaxy Resources (GXY:xasx)

Pilbara Minerals (PLS:xasx)

Western Areas (WSA:xasx)

Poseidon Nickel (POS:xasx)

Panoramic Resources (PAN:xasx)

Nickel Mines (NIC:xasx)

Iron Ore

BHP (BHP:xasx)

Rio Tinto (RIO:xasx)

Fortescue Metals (FMG:xasx)

Uranium – Supply squeeze due to low prices meets increasing demand with busiest global nuclear build program in decades

Paladin (PDN:xasx)

Lotus Resources (LOT:xasx)

Peninsula Energy (PEN:xasx)

NexGen Energy Ltd (NXE:xtse)

Bannerman (BMN:xasx)

Vimy Resources (VMY:xasx)

Rare Earths - ESG, National Security (non-Chinese supply), and EV exposure converge

US forming a Uranium + Rare Earths strategic reserve (MP Materials' Mountain Pass Mine will now become an even more valuable US strategic asset) - MP Materials Corp is one of the only ways to get exposure to American Rare Earths.

Post our initial buy recommendation in 2018, Australia-based Lynas remains in a pivotal position, as it is one of the only miner and processor/producer of rare earths worldwide outside of China.

Lynas (LYC:xasx)

MP Materials (MP:xnys)

Vaneck Rare Earth ETF (REMX:arcx)

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.